Use of Transgenic Mice in Carcinogenicity Hazard Assessment

Abstract

Determining the carcinogenic potential of materials to which humans have significant exposure is an important, complex and imperfect exercise. Not only are the methods for such determinations protracted, expensive and utilize large numbers of animals, extrapolation of data from such studies to human risk is imprecise. Toxicologists have long recognized these shortcomings but the 2-year chronic rodent study has remained the gold standard. Recent developments in the field of molecular oncology and development of methods to insert or inactivate specific genes in animals have provided the tools with which to develop the next generation of carcinogenicity assays. With improved understanding of oncogene activation and tumor suppressor gene inactivation a number of animal models have been developed to dramatically reduce latency for chemically induced cancers. This has led to the development of shorter carcinogenicity assays. Also, because the spontaneous tumor frequencies in these animals are low during the in-life portion of the study, and studies are terminated well before the health complications of advanced aging are observed, it has been possible to reduce the group sizes and reduce animal usage. FDA's adoption of ICH S1B in 1997, (ICH, 1997) “Testing for the Carcinogenicity of Pharmaceuticals,” opened the door for the use of such transgenic models in regulatory toxicology. This presentation reviews the current state of the science and its application to regulatory issues.

Keywords

Carcinogenicity testing transgenic mice p53 Tg.AC TgrasH2 regulatory toxicology.

References

Boley, S.E.

Anderson, E.E.

French, J.E.

Donehower, L.A.

Walker, D.B.

, and

Recio, L.

(2000). Loss of p53 in benzene-induced thymic lymphomas in p53 mice: evidence of chromosomal recombinationCancer Res60, 2831—5.

Donehower, L.A.

Harvey, M.

Slagle, B.L.

McArthur, M.J.

Montgomery, C.A.J.

Butel, J.S.

, and

Bradley, A.

(1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature356, 215—21.

Hansen, L.A.

, and

Tennant, R.W.

(1994). Follicular origin of epidermal papillomas in v-Ha-ras transgenic Tg.AC mouse skin. Proc Natl Acad Sci USA91, 7822—6.

ILSI/HESI Alternatives to Carcinogenicity Testing Project.

(2001). Toxicol Pathol29, 1—198.

International Conference on Harmonization, Expert Working Group on Safety (1997). Guidance for Industry S1B Testing for Carcinogencity of Pharmaceuticals, 〈www.fda.gov/cder/guidance/index.htm〉 . ICH, Geneva, Switzerland.

Jacobson-Kram, D.

Gulezian, D.

Wenk, M.L.

Lanning, L.L.

, and

Smith, G.B.

(2003). Twenty six-week validation study of the Tg.rasH2 mouse test system using three carcinogens. Toxicologist72, 1—S.

Leder, A.

Kuo, A.

Cardiff, R.

Sinn, E.

, and

Leder, P.

(1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA87, 9178—82.

Pritchard, J.B.

French, J.E.

Davis, B.J.

, and

Haseman, J.K.

(2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect111, 1—11.

Saitoh, A.

Kimura, M.

Takahashi, R.

Yokoyama, M.

Nomura, T.

Izawa, M.

Sekiya, T.

Nishimura, S.

, and

Katuski, M.

(1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene5, 1195—1200.

10.

Sistare, F.D.

, and

Jacobs, A.C.

(2003). Use of transgenic animals in regulatory carcinogenicity evaluations. In Alternative Toxicological Methods (

H. Salem

and

S. A. Katz

, eds.), pp. 391—412. CRC Press, Boca Raton, FL.

11.

Van Kreijl, C.F.

McAnulty, P.A.

Beems, R.B.

Vynckier, A.

van Steeg, H.

Fransson-Steen, R.

Alden, C.L.

Forster, R.

van der Laan, J.-W.

, and

Vandenberghe, J.

(2001). Xpa and Xpa/p53 Knockout mice: overview of available data. Toxicol Pathol29, 117—27.

12.

Van Steeg, H.

de Vries, A.

van Oostrom, C.T.M.

van Benthem, J.

Beems, R.B.

, and

van Kreijl, C.F.

(2001). DNA repair-deficient Xpa and Xpa/p53Knockout mice: nature of the models. Toxicol Pathol29, 109—16.

13.

Venkatachalam, S.

Tyner, S.D.

Pickering, C.R.

Boley, S.

Recio, L.

Frech, J.E.

, and

Donehower, L.A.

(2001). Is p53 haplo insufficient for tumor suppression? Implications for the p53 mouse model in carcinogenicity testing. Toxicol Pathol29, 147—54.

14.

Youssef, A.F.

Borellini, F.

Jacobson-Kram, D.

, and

Fort, F.

(2001). Analysis for loss of heterozygosity (LOH) of p53 allele in tumors derived from p53 and CD-1 mice following repeated subcutaneous injections of solutions containing antioxidants. Environ Molec Mutagen37, 27—30.